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Abstract
Covalent attachment of myristate and/or palmitate occurs on a wide variety of viral and cellular proteins. This review will
highlight the latest advances in our understanding of the enzymology of N-myristoylation and palmitoylation as well as the
functional consequences of fatty acylation of key signaling proteins. The role of myristate and palmitate in promoting
membrane binding as well as specific membrane targeting will be reviewed, with emphasis on the Src family of tyrosine
protein kinases and K subunits of heterotrimeric G proteins. The use of myristoyl switches and regulated depalmitoylation as
mechanisms for achieving reversible membrane binding and regulated signaling will also be explored. ß 1999 Elsevier
Science B.V. All rights reserved.
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1. Introduction
Covalent attachment of fatty acids to proteins is
now a widely recognized form of protein modi¢-
cation. Many fatty acylated proteins play key roles
in regulating cellular structure and function. Within
the past 3 years, several reviews have focused on
fatty acylation of signaling proteins [1^4]. This re-
view will highlight some of the newest advances in
protein fatty acylation, particularly with regard to
membrane binding and targeting of fatty acylated
proteins.
The two most common forms of protein fatty acyl-
ation are modi¢cation with myristate, a 14-carbon
saturated fatty acid, and palmitate, a 16-carbon sa-
turated fatty acid. The enzymology of the myristoyl-
ation reaction is well understood. Proteins that are
destined to become myristoylated begin with the se-
quence: Met^Gly. The initiating methionine is re-
moved cotranslationally by methionine amino-pepti-
dase, and myristate is linked to Gly-2 via an amide
bond. As discussed below, N-myristoylation is cata-
lyzed by N-myristoyl transferase, an enzyme that has
recently been extensively characterized. In contrast,
the enzymology of palmitoylation reaction(s) is more
complex and is poorly understood. Nearly all palmi-
toylated proteins are acylated by attachment of pal-
mitate through a thioester linkage to the sulfhydryl
group of cysteine. (One exception is Sonic hedgehog,
a protein that contains palmitate linked to the amino
group of the N-terminal cysteine [5].) The location of
these palmitoylated cysteine residues varies-some are
present near the N- or C-termini of proteins, while
others are located near transmembrane domains.
Both myristoylation and palmitoylation can be dy-
namically regulated: the myristate moiety can be se-
questered through the use of myristoyl switches,
while palmitate can be removed by protein palmitoyl
thioesterases.
2. Protein N-myristoylation
2.1. Structure and function of N-myristoyl transferase
N-myristoyl transferase (NMT) is a 50^60 kDa
monomeric enzyme that catalyzes transfer of myris-
tate from myristoyl-CoA to suitable peptide and pro-
tein substrates. To date, nearly one dozen NMTs
from fungal and mammalian sources have been iden-
ti¢ed. Studies of NMT from the yeast S. cerevisiae
reveal that the catalytic cycle exhibits the following
Bi Bi reaction mechanism [6]: (1) myristoyl CoA
binds to NMT; (2) the peptide substrate binds to
NMT; (3) myristate is transferred to the N-terminal
glycine of the peptide; (4) CoA is released from the
enzyme; (5) myristoyl-peptide is released. In cells, N-
myristoylation is a cotranslational process that oc-
curs while the nascent polypeptide chain is still at-
tached to the ribosome [7,8].
The requirements for both fatty acid and peptide
substrate speci¢cities of NMT have been character-
ized and have been extensively reviewed [9]. Myris-
tate is attached speci¢cally to the N-terminus of the
acceptor protein via an amide bond. Longer or
shorter fatty acyl CoAs are poor substrates, and their
corresponding fatty acids are generally not trans-
ferred by NMT to acceptor proteins. It is interesting
to note that palmitoyl CoA binds to NMT with
approximately the same Km as myristoyl CoA,
although palmitate is not transferred by NMT to
proteins. Since the concentration of palmitoyl CoA
is 5^20-fold higher than myristoyl CoA in most
cells, a mechanism must exist to prevent palmitoyl
CoA from functioning as a competitive inhibitor of
NMT in vivo. It has been proposed that due to its
higher hydrophobicity, most of the palmitoyl CoA is
sequestered in cell membranes and therefore is not
accessible to cytoplasmic NMT [9,10].
Several N-myristoylated proteins, including recov-
erin, transducin and protein kinase A, have been
shown to be heterogeneously fatty acylated, contain-
ing 12:0, 14:1 and 14:2 fatty acids in addition to
14:0 myristate [11,12]. Examination of N-myristoyl-
ated proteins in di¡erent tissues reveals that hetero-
genous N-acylation is primarily restricted to the ret-
ina [9,13]. The reason for the retina-speci¢c nature of
heterogenous acylation is not clear, as the fatty acyl
CoA pools in retina appear nearly identical to those
in other tissues [13].
The consensus sequence for NMT protein sub-
strates is: Met^Gly^X^X^X^Ser/Thr^. The initiating
Met is removed by methionine amino peptidase dur-
ing translation and Gly-2 becomes the N-terminal
amino acid. The requirement for Gly at the N-termi-
nus is absolute; no other amino acid will substitute.
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Table 1
N-Myristoyolated proteins: sequence and function
1. Protein kinases and phosphatases
Src family tyrosine kinases
Src M G S S K S K P K D P S Q R R R
Yes M G C I K S K E D K G P A M K Y
Fyn M G C V Q C K D K E A T K L T E
Lyn M G C I K S K R K D N L N D D E
Lck M G C V C S S N P E D D W M E N
Hck M G C M K S K F L Q V G G N T G
Fgr M G C V F C K K L E P V A T A K
Yrk M G C V H C K E K I S G K G Q G
Blk M G L L S S K R Q V S E K G K G
Abl tyrosine kinases
c-Abl M G Q Q P G K V L G D Q R R P S
Arg M G Q Q V G R V G E A P G L Q Q
Serine/threonine kinases and anchoring proteins
cAMP-Dependent
protein kinase,
catalytic subunit
Alpha M G N A A A A K K G S E Q E S V
Beta-1 M G N A A T A K K G S E V E S V
Yeast protein kinase
VPS15
M G A Q L S L V V Q A S P S I A
MPSK M G H A L C V C S R G T V I I D
AKAP18 M G Q L C C F P F S R D E G K I
Phosphatases
Calcineurin B M G N E A S Y P L E M C S H F D
Yeast phosphatase
PP-Z2
M G N S G S K Q H T K H N S K K
2. Guanine nucleotide binding proteins
GK proteins
GKi1 M G C T L S A E D K A A V E R S
GKo M G C T L S A E E R A A L E R S
GKt M G A G A S A E E K H S R E L E
GKx M G C R Q S S E E K E A A R R S
ADP-ribosylation factors
Arf-1 M G L S F T K L F S R L F A K K
Arf-3 M G N I F G N L L K S L I G K K
Arf-5 M G L T V S A L F S R I F G K K
Arf-6 M G K V L S K I F G N K E M R I
3. Ca2 binding/EF hand proteins
Recoverin M G N S K S G A L S K E I L E E
Neurocalcin M G K Q N S K L R P E V M Q D L
Aplycalcin M G K R A S K L K P E E V E E L
Visinin-like protein 3 M G K Q N S K L R P E V L Q D L
Ca2 binding protein
P22
M G S R A S T L L R D E E L E E
NAP-22 M G S K L S K K K K G Y N V N D
Hippocalcin M G K Q N S K L R P E M L Q D L
GCAP 1 M G N V M E G K S V E E L S S T
GCAP 2 M G Q Q F S W E E A E E N G A V
S-Modulin M G N T K S G A L S K E I L E E
Rem-1 M G K Q N S K L R P E V L Q D L
Table 1 (continued)
4. Membrane- and cytoskeletal-bound structural proteins
MARCKS M G A Q F S K T A A K G E A T A
MAC-MARCKS M G S Q S S K A P R G D V T A E
Annexin XIII M G N R H A K A S S P Q G F D V
Rapsyn M G Q D Q T K Q Q I E K G L Q L
Pallidin (Band 4.2) M G Q A L S I K S C D F H A A E
Hisactophilin 2 M G N R A F K A H N G H Y L S A
5. Viral proteins
Gag proteins
HIV-1 M G A R A S V L S G G E L D R W
Moloney murine
sarcoma virus
M G Q T V T T P L S L T L D H W
Friend murine
leukemia virus
M G Q A V T T P L S L T L D H W
Bovine leukemia virus M G N S P S Y N P P A G I S P S
Baboon endogenous
virus
M G Q T L T T P L S L T L T H F
Feline sarcoma virus
(G-R)
M G Q T I T T P L S L T L D H W
FBR murine
osteosarcoma virus
M G Q T V T T P L S L T L E H W
Mason^P¢zer monkey
virus
M G Q E L S Q H E R Y V E Q L K
Mouse mammary
tumor virus
M G V S G S K G Q K L F V S V L
Other viral proteins
HIV-1 Nef M G G K W S K S S V V G W P T V
Duck hepatitis B virus M G Q H P A K S M D V R R I E G
Rhinovirus 16 M G A Q V S R Q N V G T H S T Q
Herpes simplex virus
Ul11
M G L A F S G A R P C C C R H N
African swine fever
virus pp220
M G N R G S S T S S R P P L S S
Chlorella virus Vp260 M G S Y F V P P A N Y F F K D I
6. Miscellaneous
NADH cytochrome b5
reductase
M G A Q L S T L S R V V L S P V
Nitric oxide synthase M G N L K S V G Q E P G P P C G
Enteropeptidase
precursor
M G S K R S V P S R H R S L T T
(2P,5P) OligoA
synthetase
M G N G E S Q L S S V P A Q K L
NADH-Ubiquinone
Oxidoreductase
M G A H L V R R Y L G D A S V E
BASP1 M G G K L S K K K K G Y N V N D
FRS2 M G S C C S C P D K D T V P D N
cPLA2-Q M G S S E V S I I P G L Q K E E
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However, not all proteins with an N-terminal glycine
are N-myristoylated and the ability to be recognized
by NMT depends on the downstream amino acid
sequence. In general, serine or threonine is preferred
at position 6 and lysine or arginine is preferred at
positions 7 and/or 8 (Table 1).
In fungi, deletion of the gene encoding NMT re-
sults in recessive lethality [14], suggesting that NMT
may be an attractive anti-fungal target. Since fungal
and human NMTs have overlapping but distinct sub-
strate speci¢cities, it should be possible to design
compounds that inhibit fungal, but not human
NMT. Depeptidized fungal NMT inhibitors that
have recently been developed [15,16] show promise
as fungicidal agents in Candida albicans and Crypto-
coccus neoformans, two organisms responsible for
systemic fungal infections in immunocompromised
individuals.
Although fungal NMT is encoded by a single copy
gene, a recent report has documented the existence of
two genes for NMT in mammalian cells [17]. The
two isoforms, NMT-1 and NMT-2, share 77% iden-
tity, are both ubiquitously expressed, and exhibit
similar substrate speci¢cities. NMT-2 migrates as a
single 65 kDa band on polyacrylamide gels, while
NMT-1 exhibits multiple isoforms ranging from 49
to 68 kDa [17,18]. Some of these isoforms may be the
result of alternative splicing [19].
In mammalian cells, the majority of the NMT ac-
tivity is localized to the cytoplasm [17]. However, a
signi¢cant proportion of the total NMT protein de-
tected by Western blotting is evident in membrane
fractions [20,21]. The amount of NMT activity in the
membrane may be underestimated as the existence of
membrane associated NMT inhibitors has been re-
ported [22]. In addition, some of the membrane frac-
tion may represent NMT bound to ribosomes. An
amino-terminal sequence derived from an upstream
start site within the NMT cDNA has been implicated
in ribosomal targeting [23].
Within the past year, two fungal NMT structures
were determined by X-ray crystallography [24,25].
Both studies reveal that NMT is a compact, globular
molecule that exhibits no structural homology to
other proteins. The structure of the yeast Saccharo-
myces cerevisiae NMT1p was solved as a ternary
complex and reveals how myristoyl CoA and peptide
substrates bind to the enzyme [25]. Myristoyl-CoA
binds in a conformation similar to a question mark
and, together with C-terminal regions of NMT,
forms a portion of the peptide binding site. The
structure allows identi¢cation of speci¢c residues
within NMT that serve to restrict substrate speci¢city
to 14-carbon fatty acids and account for the prefer-
ence for gly-2, ser-6, and basic amino acids at posi-
tions 7 and 8 of the peptide substrate. The C-termi-
nal carboxylate was also shown to play a critical role
in catalysis by binding to the N-terminal glycine am-
monium group in the peptide substrate. The latter
result explains why deletion of C-terminal residues
inhibits NMT activity.
2.2. Functions of protein N-myristoylation
2.2.1. Structural roles
X-Ray crystallography of several N-myristoylated
proteins has revealed how myristate can play a struc-
tural role to stabilize three-dimensional protein con-
formation. Poliovirus is a non-enveloped virus that
requires myristoylation of its VP4 protein for virus
assembly. The electron density map revealed that the
myristate moiety forms an integral part of the virion
subunit structure [26]. In the catalytic subunit of
PKA, myristate is positioned within a hydrophobic
pocket and is required for structural and thermo-
stability of the enzyme [27]. Crystal structures of re-
coverin and Arf-1 also reveal binding sites for myr-
istate in hydrophobic pockets or grooves within the
protein’s three-dimensional structure (see below).
These structures provide evidence that myristate
does not always ‘stick out’ of a protein.
2.2.2. Membrane binding
Many N-myristoylated proteins are membrane
bound and can be found in the plasma membrane
or other intracellular membranes in eukaryotic cells.
Abrogation of myristoylation, by mutation of Gly2
to Ala, generally results in reduction or loss of mem-
brane binding. For example, studies of pp60v-src, the
transforming protein of Rous sarcoma virus, have
clearly established that myristoylation is necessary
for directing the Src protein to the membrane. Non-
myristoylated Src mutants do not bind to mem-
branes and do not mediate cellular transformation
[28,29]. Likewise, retroviral and lentiviral Gag pro-
teins require myristoylation in order to bind to the
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plasma membrane and mediate virus particle forma-
tion. Mutation of Gly-2 to Ala prevents myristoyla-
tion and inhibits membrane binding of Moloney
murine leukemia virus, spleen necrosis virus and
HIV-1 Gag proteins [30^33]; virus assembly by these
mutants is blocked.
While myristoylation is clearly necessary for mem-
brane binding of some proteins, it is not su⁄cient.
Biophysical studies have established that the binding
energy provided by myristate is relatively weak (ap-
proximately 1034 M Kd) and not su⁄cient to fully
anchor a peptide or protein to a cellular membrane
[10]. A second signal within the N-myristoylated pro-
tein is therefore required for e⁄cient membrane
binding.
2.2.3. The two-signal model for membrane binding of
N-myristoylated proteins
The second signal for membrane binding of N-
myristoylated proteins has been de¢ned as either a
polybasic cluster of amino acids or a palmitate moi-
ety (Fig. 1). It should be noted that a similar two
signal model applies to membrane binding of farne-
sylated proteins, e.g., Ras [34,35]. Proteins that use a
‘myristate plus basic’ motif for membrane binding
will be considered here, and those that use a ‘myris-
tate plus palmitate’ signal will be considered in the
next section.
The biophysical basis for membrane binding by
‘myristate plus basic’ motifs is now well established
[36^39]. Myristate inserts hydrophobically into the
lipid bilayer, and approximately 10 of the 14 carbons
penetrate the hydrocarbon core of bilayer [39]. The
basic amino acids form electrostatic interactions with
the headgroups of acidic phospholipids [40]. In the
plasma membrane, these acidic phospholipids (pri-
marily PS and PI) are localized primarily to the inner
lea£et of the bilayer, imparting a net negative charge
to the cytoplasmic lea£et surface. Neither the hydro-
phobic nor the electrostatic interactions alone are
su⁄cient to provide strong membrane binding. How-
ever, when both myristate and a basic motif are
present within the protein, the hydrophobic and elec-
trostatic forces synergize. For example, the presence
of six basic residues in the N-terminal region of Src
enhances its binding to membranes containing acidic
phospholipids nearly 3000-fold. The myristate plus
basic motif mediates binding of Src to membranes
Fig. 1. The two-signal model for membrane binding of myristoylated proteins. In order to achieve stable membrane binding, myristoyl-
ated proteins require a second membrane binding signal. This can be provided in several ways. A cluster of basic residues can provide
electrostatic interactions with acidic phospholipid headgroups in the inner lea£et of the bilayer (myristate+basic). One or two palmi-
tate moieties can provide additional hydrophobic interaction with the bilayer (myristate+palmitate). Alternatively, membrane interac-
tion of singly acylated proteins can be enhanced by protein^protein interactions with other membrane bound proteins.
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in vitro and in vivo and is required for cellular trans-
formation by v-Src [36,37].
Several other proteins have been shown to utilize a
myristate plus basic motif for membrane binding,
including the MARCKS protein (see below), HIV-1
Gag and HIV-1 Nef proteins [38,41]. The Gag poly-
proteins mediate assembly of type C retroviruses and
lentiviruses at the plasma membrane and form the
structural elements of the virion core. Like Src,
HIV-1 Gag contains a myristate plus basic motif at
its N-terminus that is necessary and su⁄cient for
plasma membrane binding [38,42,43]. The myristate
plus basic motifs of Src and Gag are functionally
interchangeable: a Gag-Src chimera can mediate
cell transformation [38], and a Src-Gag chimera can
generate viral particles [44]. Examination of the myr-
istate plus basic motif of HIV-1 Gag reveals that the
cluster of basic amino acids forms an amphipathic L-
pleated sheet, with nearly all of the positively
charged residues oriented on the top surface of the
molecule and poised to interact with acidic mem-
brane phospholipids [38,45^47].
2.2.4. Membrane targeting speci¢city
For some proteins, the myristate moiety provides
not only membrane binding, but also membrane
targeting functions. For example, when Src or Gag
N-terminal sequences are attached to soluble pro-
teins, the chimeras display speci¢c localization to
the plasma membrane [39,43]. Conversely, mutation
of N-myristoylation sites in the yeast Gpa 1p protein
or in HIV-1 Gag redirect the proteins to intracellular
membranes, implying that myristate participates in
plasma membrane targeting [48,49]. In Mason^P¢zer
monkey virus, virion cores are assembled in the cy-
tosol and myristoylation of Gag is required for intra-
cellular transport to the plasma membrane [50].
How myristate plus basic motifs mediate plasma
membrane targeting speci¢city is not known. It is
possible that the plasma membrane contains higher
concentrations of acidic phospholipids, compared to
intracellular membranes, or that these phospholipids
are enriched in plasma membrane microdomains.
Alternatively, additional protein^protein interactions
may occur at the plasma membrane that serve
to preferentially enhance the binding of certain N-
myristoylated proteins to the plasma membrane
(Fig. 1).
2.3. Regulation of membrane binding of
N-myristoylated proteins
2.3.1. Alteration of myristoylation levels
The amide bond that links myristate to the N-ter-
minal glycine is relatively stable, and in general the
half-life of myristate on a protein is equivalent to the
half-life of the polypeptide chain backbone [51].
However, demyristoylation of the MARCKS protein
in brain [52] and of a 68 kDa protein in Dictyoste-
lium discoideum [53] has been described. Experiments
in yeast have documented the existence of a nonmyr-
istoylated pool of Gpa 1p [54]. It is not known how
pools of nonmyristoylated proteins are created and
maintained.
2.3.2. Myristoyl switches
The orientation of the myristoyl moiety relative to
the protein to which it is attached is not always stat-
ic. Some N-myristoylated proteins exist in two con-
formations. In one conformation, the myristate moi-
ety is sequestered in a hydrophobic pocket within the
protein. In the alternate conformation, myristate is
£ipped out and becomes available to participate in
membrane binding. The transition between these two
states is regulated by a mechanism known as the
‘myristoyl switch’. Proteins that are subject to a myr-
istoyl switch typically exhibit reversible membrane
binding (Fig. 2). The triggers for the switch fall
into three general categories: ligand binding, electro-
statics, and proteolysis.
2.3.3. Myristoyl^ligand switches
Two of the best examples of ligand mediated myr-
istoyl switch proteins are recoverin and Arf (ADP
ribosylation factor). For both of these proteins, there
is ample biochemical as well as structural evidence to
substantiate a myristoyl switch mechanism of re-
versible membrane binding. Recoverin is a calcium
binding protein in the retina that inhibits rhodopsin
kinase and thereby regulates the phosphorylation
level of photoexcited rhodopsin. In the Ca2-free
state, the myristoyl group is sequestered in a hydro-
phobic pocket formed by hydrophobic and aromatic
residues [55,56]. Binding of Ca2 induces a confor-
mational change within recoverin; the myristate is
unclamped and ejected, thereby allowing membrane
binding [55]. The residues important for Ca2-medi-
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ated expulsion of myristate are conserved in other
members of the recoverin family and several of these
family members have been to shown to display a
similar calcium^myristoyl switch. Arf proteins con-
stitute another family of ligand-regulated myristoyl
switch proteins in which guanine nucleotide binding
regulates the exposure of the myristate moiety
[57,58]. In the GDP-bound form, the myristoylated
N-terminal helix is cradled in a shallow hydrophobic
groove formed by loop V3 within Arf-1 [59]. Binding
of GTP triggers extrusion of loop V3 and its contin-
uous surfaces, resulting in expulsion of and subse-
quent membrane binding by the myristoylated N-ter-
minus [60].
2.3.4. Myristoyl^electrostatic switches
The MARCKS protein is a protein kinase C
(PKC) substrate whose membrane binding is regu-
lated by a myristoyl electrostatic switch [61]. As
discussed above, binding of nonphosphorylated
MARCKS to membranes is mediated by its myris-
tate plus basic motif. Phosphorylation of MARCKS
by PKC occurs within the MARCKS basic domain,
resulting in introduction of negative charges into the
positively charged region. This reduces the electro-
static interactions with acidic phospholipids and re-
sults in displacement of MARCKS from the mem-
brane and into the cytosol [62]. The myristoyl switch
and membrane release can be prevented by replacing
the N-terminal sequence of MARCKS with that of
GAP-43, a dually palmitoylated protein [63]. The
GAP43/MARCKS chimera remains at the mem-
brane, even when phosphorylated by PKC, presum-
ably because insertion of two palmitates into the bi-
layer provides stable membrane association.
Fibroblasts expressing the GAP43/MARCKS chi-
mera are impaired in cell spreading, a ¢nding that
illustrates the functional importance of the myristoyl
switch [64].
An additional example of a myristoyl^electrostatic
switch is provided by hisactophilin, a histidine-rich
actin binding protein in Dictyostelium. Hisactophilin
has a cluster of basic residues including seven histi-
dines near the N-terminal myristate. Increasing the
pH above 7 titrates the charge of the histidines and
triggers a myristoyl-histidine switch which reduces
membrane binding a⁄nity [65].
Another potential candidate for a myristoyl-elec-
trostatic switch is Src. The myristate plus basic motif
of the Src protein contains sites for phosphorylation
by PKC and PKA. Phosphorylation of either site
reduces the partitioning of model Src peptides onto
lipid bilayers by 10-fold [39]. However, unlike
MARCKS, translocation of Src from the membrane
to the cytosol upon phosphorylation has not been
Fig. 2. Myristoyl switches are mechanisms for reversible mem-
brane binding. (A) Myristoyl^ligand switch. Binding of ligand
triggers a conformational change that regulates exposure of the
myristate moiety. In one conformation, myristate is sequestered
within a hydrophobic cleft of the protein. In the alternative
conformation, myristate is ‘£ipped out’ and promotes mem-
brane binding. (B) Myristoyl^electrostatic switch. The
MARCKS protein is bound to the plasma membrane by a myr-
istate+basic motif. Phosphorylation by PKC within the basic
region reduces the electrostatic contribution and results in re-
lease of the protein from the membrane. (C) Myristoyl^proteo-
lytic switch. The HIV-1 Gag precursor, Pr55gag, binds to the
plasma membrane via a myristate+basic motif. Cleavage of
Pr55gag by HIV-1 Protease (Pr) triggers a myristoyl switch that
results in formation of the p17MA product, sequestration of
myristate, and release of p17MA from the membrane.
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consistently demonstrated [39,66]. Since the partition
coe⁄cient for monophosphorylated Src is about 104
M31 and the accessible lipid concentration in a typ-
ical cell is estimated to be 1033 M, most of the
monophosphorylated Src would be expected to re-
main membrane bound [39].
2.3.5. A myristoyl^proteolytic switch
HIV-1 Gag provides the most recent example of a
protein whose membrane binding is regulated by a
myristoyl switch. Gag is synthesized as a polyprotein
precursor (Pr55gag) that is directed to the plasma
membrane by a myristate plus basic motif [38]. Dur-
ing virus assembly, Gag is cleaved by the viral pro-
tease. The N-terminal cleavage product, p17MA, re-
tains the same N-terminal sequence as Pr55gag, yet
p17MA binds weakly to membranes [43,67]. The ba-
sis for the di¡erential membrane binding of p17MA
compared to Pr55gag has been attributed to a myr-
istoyl switch in which myristate is accessible within
Pr55gag but sequestered within p17MA. Cleavage of
Pr55gag by HIV-1 protease has recently been shown
to be the trigger for the myristoyl switch [68]. Release
of p17MA from the membrane is important for viral
infectivity, as the matrix protein forms a component
of the preintegration complex that translocates to the
nucleus upon HIV-1 infection [69].
3. Protein palmitoylation
3.1. Enzymology of palmitoylation
3.1.1. Palmitoyl acyl transferase (PAT)
In contrast to N-myristoylation, the identity(ies) of
the enzyme(s) responsible for protein palmitoylation
have not yet been ¢rmly established. This is directly
related to the extreme di⁄culty that investigators
have experienced in attempting to obtain adequate
amounts of puri¢ed PAT protein for analysis. To
complicate matters, there are numerous reports doc-
umenting the existence of mechanisms for nonenzy-
matic palmitoylation of proteins. The pros and cons
of enzymatic versus nonenzymatic protein palmitoyl-
ation will be discussed below.
Two groups have reported partial puri¢cation of
enzyme activities responsible for palmitoylation of
Src family kinases and GK protein subunits [70,71].
Both PAT’s exhibit a preference for myristoylated
protein substrates and for palmitoyl CoA over other
fatty Acyl CoA substrates. These PATs are mem-
brane bound and the PAT that palmitoylates GK
proteins is enriched in the plasma membrane [71].
Three additional reports have appeared recently in
which PATs have been puri¢ed to homogeneity. A
70 kDa PAT was described that palmitoylates red
blood cell spectrin; it is not known whether other
proteins will serve as substrates [72]. Using a non-
prenylated Drosophila Ras peptide as substrate, a
PAT activity was puri¢ed and its cDNA cloned
from Bombyx mori [73]. This PAT consists of two
polypeptides that both contain structural features
found in fatty acid synthase, an enzyme that cata-
lyzes palmitate synthesis. Gelb and coworkers also
used Ras as a substrate and puri¢ed a PAT that
transfers palmitate from palmitoyl-CoA to C-termi-
nal cysteines in H-Ras [74]. Further puri¢cation and
sequencing revealed that the PAT activity was cata-
lyzed by thiolase A, an enzyme that participates in
the terminal steps of L-oxidation of fatty acids [75].
Since thiolase is localized in organelles (mitochondria
and peroxisomes) and typically catalyzes hydrolysis
rather than transfer of palmitate, its relevance for
palmitoylation of plasma membrane bound Ras is
not yet apparent.
The sulfhydryl group of cysteine is a good nucle-
ophile and so it is not surprising that under appro-
priate conditions one can observe nonenzymatic pal-
mitoylation of proteins (GK) and peptides (c-Yes) in
vitro [76,77]. Many of the characteristics of nonenzy-
matic palmitoylation are similar to those expected
for PAT, including a dependence on time, substrate
concentration, and the presence of myristate on the
protein or peptide substrate. However, two lines of
evidence argue against a nonenzymatic mechanism
for protein palmitoylation in vivo. First, the reaction
kinetics for nonenzymatic acylation appear to be too
slow to account for rapid palmitoylation of signaling
proteins. Transacylation of GK subunits in vitro oc-
curs with a time scale of tens of minutes. Estimates
for spontaneous acylation of proteins in vivo are in
the tens-of-hours range. This estimate is based on the
existence of acyl CoA binding proteins that sequester
long chain fatty acyl CoAs and severely reduce their
intracellular concentration and therefore the rate of
nonenzymatic transfer to proteins [78]. Second, se-
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quence speci¢cities for protein S-acylation exist that
are di⁄cult to rationalize with a nonenzymatic acyl-
ation process. For example, hemagglutinin (HA)
and hemagglutinin esterase fusion (HEF) proteins
are plasma membrane bound glycoproteins from
the same virus (in£uenza). In mammalian cells, HA
is palmitoylated, whereas HEF is primarily modi¢ed
with stearate. Replacement of the C-terminal tail of
HEF with that of HA results in a chimeric protein
that is palmitoylated. Moreover, when HEF is ex-
pressed in insect cells it is mostly palmitoylated, de-
spite the fact that stearoyl CoA is present in the
insect cells [79]. These ¢ndings of acyl chain selectiv-
ity cannot readily be explained by an uncatalyzed
mechanism. Studies with the Fyn tyrosine kinase
also indicate a clear di¡erence between nonenzymatic
palmitoylation in vitro and the palmitoylation reac-
tion occurring in cells. A Fyn mutant in which cys-
teines 3 and 6 are changed to serine can be palmi-
toylated nonenzymatically in vitro (A. Wolven and
M.D. Resh, unpublished results), but little or no
palmitoylation of this mutant occurs in vivo
[51,80]. Mutation of the same cysteines to alanine
residues blocks palmitoylation of Fyn in vivo and
in vitro. This implies that nonenzymatic fatty acyla-
tion of Fyn does not occur to any signi¢cant extent
in vivo. Taken together, the available evidence
strongly suggests that PATs exist, but in the absence
of de¢nitive identi¢cation, it remains possible that
nonenzymatic mechanisms may contribute to fatty
acylation of certain proteins.
3.1.2. Palmitoyl protein thioesterases
Two thioesterases, PPT1 and APT1, have been
identi¢ed that deacylate Ras and GK proteins in vi-
tro. PPT1 is unlikely to mediate depalmitoylation of
plasma membrane bound proteins in vivo as it is
localized to the lysosome [81]. Further analysis re-
vealed that PPT1 is mutated in a speci¢c lysosomal
storage disease, infantile neuronal ceroid lipofuscino-
sis. Individuals with PPT1 mutations accumulate
small lipid thioesters that are the likely substrates
for PPT1 [82]. A related palmitoyl thioesterase,
PPT2, was recently described [83]. PPT2 will only
remove palmitate from palmitoyl CoA, not from pal-
mitoylated protein substrates. In contrast, Duncan
and Gilman have puri¢ed an acyl protein thioester-
ase (APT1) that depalmitoylates GK subunits and
Ras in vitro and GKs in vivo [84]. Interestingly,
APT1 had originally been identi¢ed by others as
a lysophospholipase, although the enzyme clearly
prefers palmitoylated protein substrates over lipid
substrates. It is likely that additional palmitoyl pro-
tein thioesterases exist and further studies will be
needed to elucidate the substrate speci¢cities of these
enzymes for di¡erent classes of palmitoylated pro-
teins.
3.1.3. Substrates
3.1.3.1. Fatty acids. The preferred substrate for
PAT appears to be palmitoyl CoA [70,71]. However,
several ‘palmitoylated’ proteins have also been
shown to incorporate other long chain fatty acids,
including stearate, oleate and arachidonate. Thus,
the term ‘S-acylation’ provides a more accurate de-
scription of this type of fatty acid modi¢cation [85].
For example, base hydrolysis of total heart and liver
proteins reveals the presence of detectable levels of
thioester linked 14:0, 18:0, 18:1, 18:2 fatty acids in
addition to C16:0 [13]. GK subunits [86], myelin
[87], P-selectin [88], asialoglycoprotein receptor [89]
and various platelet proteins [90] have been shown
to heterogeneously S-acylate with stearate and
arachidonate. Whether acylation with di¡erent fatty
acids a¡ects protein function has not yet been deter-
mined.
3.1.3.2. Protein sequences. A previous review [1]
categorized palmitoylated proteins into four types
(Table 2). Type I sequences consist of plasma mem-
brane receptors and other membrane proteins that
are typically palmitoylated on one or several cysteine
residues located adjacent to or just within the trans-
membrane domain. Both the length and composition
of the transmembrane sequences as well as the length
of the cytoplasmic tail appear to in£uence the choice
of fatty acid for acylation. Proteins with short basic
tails are modi¢ed with stearate, while those with lon-
ger tails are primarily palmitoylated [91^93]. Type II
proteins include members of the Ras family that are
modi¢ed with a farnesyl moiety in their C-terminal
CAAX box. Prenylation of Ras is required for sub-
sequent palmitoylation of cysteines in the C-terminal
region [94]. A third group of proteins (Type III) are
palmitoylated at cysteine residues near the N- or C-
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termini. Type IV proteins are dually fatty acylated
with myristate and palmitate and nearly all (the ex-
ceptions being eNOS and AKAP18) contain the con-
sensus sequence Met^Gly^Cys at their N-termini.
Myristoylation of Gly-2 facilitates palmitoylation of
Cys-3, but the requirement for myristate can be by-
passed by targeting the protein to the plasma mem-
brane via other means [95,96].
Table 2
Palmitoylated protein sequences
Type I: Transmembrane, integral or peripheral membrane proteins
TGFK ... EKPSALLKGRTACCHSETVV
Transferrin receptor ...KANVTKPKRCSGSICYGT...
P-Selectin ...KDDGKCPLNPHS
CD4 ...GIFFCVRCRHRRRQ...
CD36 MGCDRNC..... CACRSKTIK
Caveolin-1 ...VPCIKSFLIEIQCISRVYSIYVHTFCDPFF...
Band 3 ...FTGIQIICLAVLWVV...
SNAP-25 ...LGKFCGLCVCPCNKLKSSDA...
Viral proteins
In£uenza HA, H1 subtype ...MCSNGSLQCRICI
Sindbis virus E2 protein ...PTSLALLCCVRSANA
Sindbis virus 6K protein ...RCCSCCLPF
VSV G protein ...RVGIHLCIKLKHTKK...
HIV-1 gp160 ...DDLRSLCLFSYHRLRD...
Rift valley fever virus G2 ...FSSIAIICLAVL...
Seven transmembrane receptors
K2A adrenergic receptor ...RRAFKKILCRGDRKRIV
L2 adrenergic receptor ...FQELLCLRRSSLK...
Dopamine D1 receptor ...LGCYRLCPAT...
LH/hCG receptor ...LLSRFGCCKRRAELYRRK...
Endothelin A receptor ...FQSCLCCCCYQSKS...
Endothelin B receptor ...KRFKNCFKSCLCCWCQSFEE...
Vasopressin receptor ...SVSSELRSLLCCARGRTPPS...
Neurokinin B receptor ...RAGFKRAFRWCPFIQVSSYD...
Serotonin receptor ...HKLIRFKCTS
Somatostatin receptor 5 ...FRQSFQKVLCLRKGSGAKDA...
Rhodopsin ...MVTTLCCGKNPLGD...
Type II: Prenylated, palmitoylated proteins
H-Ras ...SGPGCMSCKCVLS
N-Ras ...GTQGCMGLPCVVM
K-Ras(A) ...TPGCVKIKKCVIM
Paralemmin ...DMKKHRCKCCSIM
Type III: Palmitoylation within an N-terminal or C-terminal region
GK subunits
Ks MGCLGNSKTEDQRNE
Kq MTLESIMACCLSEEAKEA
K12 MSGVVRTLSRCLLPAEAG
K13 MADFLPSRSVCFPGCVLTN
K16 MARSLRWRCCPWCLTEDEKAA
GAP43 MLCCMRRTKQVEKNDDDQKIEQDGI
Ca2 channel L2a subunit MQCCGLVHRRRVRV
PSD-95 MDCLCIVTTK KYRYQDEDTP
RGS4 MCKGLAGLPA SCLRSAKDMK
GRK6 ...FSRQD CCGNCSDSEE ELPTRL
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3.2. The role of palmitoylation in membrane binding
and plasma membrane targeting
The function of the palmitate moiety in fatty acyl-
ated proteins has primarily been inferred by mutat-
ing the modi¢ed cysteine residue(s) to serine or ala-
nine and observing the behavior of the mutant
protein. While mutational analysis is extremely use-
ful, the possibility remains that an observed pheno-
type may be due to the loss of the cysteine residue
per se, rather than loss of the palmitate [2^4].
3.2.1. Dually fatty acylated proteins
The myristate plus palmitate two-signal motif en-
coded by the Met^Gly^Cys sequence is both neces-
sary and su⁄cient to direct Src family kinases as well
as GK proteins to the plasma membrane [51,80,97^
101]. Mutation of Gly-2 and/or Cys-3 reduces or
eliminates membrane binding and plasma membrane
targeting. Moreover, attachment of the N-terminal
sequences of Fyn, Lck or GKi to heterologous cyto-
solic proteins redirects the chimeras to the plasma
membrane. The biochemical basis for membrane
binding by the myristate plus palmitate signal is
clear: two fatty acids are better than one [102].
This explanation also pertains to dually palmitoyl-
ated proteins that are not myristoylated but contain
two sites for palmitoylation (e.g., GAP43 and certain
GK subunits), as well as palmitoylated, farnesylated
proteins such as H-Ras [103].
An excellent model has recently been advanced to
account for the ability of palmitoylated proteins to
be speci¢cally targeted to the plasma membrane. The
‘kinetic bilayer trapping’ hypothesis [102] proposes
that proteins with a single lipophilic group (myristate
or farnesyl) transiently interact with multiple intra-
cellular membranes. Acylated protein that reaches
the plasma membrane will be rapidly palmitoylated
by a plasma membrane bound PAT and remain sta-
bly attached to the plasma membrane because of the
strong hydrophobicity and the slow kinetic o¡ rate
of the dual fatty acyl anchor. Several lines of evi-
dence support this model. First, a PAT that palmi-
toylates GK subunits has been shown to be enriched
in the plasma membrane [71]. Second, myr^gly^cys-
containing peptides, as well as farnesylated N-Ras
peptides, are speci¢cally palmitoylated at and remain
bound to the plasma membrane [104,105]. Third, the
N-terminal myr^gly^cys motif has been shown to
promote rapid plasma membrane targeting of the
Src family kinase Fyn. Mutation of the Cys-3 palmi-
toylation site reduces the rate of membrane binding
and redirects the protein to intracellular membranes
[51,98].
Proteins that are acylated with two or more pal-
mitates rather than myristate plus palmitate, appear
to take a di¡erent route to the plasma membrane.
For example, SNAP25 and GAP43 require nearly 20
min for palmitoylation and plasma membrane bind-
ing [106]. Unlike Fyn, which goes directly to the
plasma membrane within 2^5 min after biosynthesis,
GAP43 and SNAP-25 travel through the secretory
Table 2 (continued)
Type IV: Myristoylated, palmitoylated proteins
Src family tyrosine kinases
Yes MGCIKSKEDKGPAMKY
Fyn MGCVQCKDKEATKLTE
Lyn MGCIKSKRKDNLNDDE
Lck MGCVCSSNPEDDWMEN
Hck MGCMKSKFLQVGGNTG
Fgr MGCVFCKKLEPVATAK
Yrk MGCVHCKEKISGKGQG
GK subunits
Ki1 MGCTLSAEDKAAVERS
Ko MGCTLSAEERAALERS
Kz MGCRQSSEEKEAARRS
AKAP18 MGQLCCFPFSRDEGK
eNOS MGNLKSVGQEPGPPCGLGLGLGLGLCGK
Palmitoylated cysteine residues are in bold and underlined.
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pathway [106]. Replacement of the N-terminal SH4
motif of Fyn with the N-terminal 10 amino acids of
GAP43 results in a chimeric protein with slow mem-
brane binding kinetics [98]. These results indicate
that at least two di¡erent pathways operate for mem-
brane targeting and plasma membrane binding of
palmitoylated proteins.
3.2.2. Targeting of palmitoylated proteins to plasma
membrane rafts
It is now recognized that rather than being a vast
continuous ‘sea’ of lipid, the plasma membrane con-
tains discrete microdomains enriched in speci¢c types
lipids and proteins. There has recently been much
interest in microdomains which are referred to as
‘rafts’. Rafts are characterized by a relative resistance
to extraction with cold, nonionic detergents, enrich-
ment in sphingolipids and cholesterol, and the pres-
ence of GPI-anchored proteins. They have also been
called DRMs, detergent resistant membranes, or
DIGs, detergent insoluble glycosphingolipid enriched
membranes and the absolute distinction among and
between these terms has been reviewed [107,108].
Several recent reports have con¢rmed that small sub-
micron domains do exist at the surface of living cells
and that these rafts contain GPI-anchored proteins
[109^111].
Lipids in rafts appear to be present in a liquid
ordered phase, and primarily contain saturated fatty
acyl chains [108]. Many proteins that are acylated
with saturated fatty acids such as myristate and pal-
mitate have been reported to be localized to raft-like
membranes. However, these proteins are localized to
the cytoplasmic surface of the plasma membrane,
and the inner lea£et of the plasma membrane bilayer
has a di¡erent lipid composition compared to the
outer lea£et. Myristoylated and palmitoylated pro-
teins such as the Src family kinases, eNOS, and GK
subunits appear to be enriched in membrane micro-
domains known as caveolae [112,113]. Caveolae are
50^70 nm microinvaginations of the plasma mem-
brane that are detergent resistant and enriched in a
marker protein, caveolin.
The mechanism responsible for accumulation of
dually acylated proteins to microdomains has not
yet been elucidated. Kinetic studies have established
that targeting of dually acylated Src kinases to the
plasma membrane occurs ¢rst, followed by a slower
partitioning to detergent-resistant microdomains [98].
Palmitoylation is required for localization of myris-
toylated Src kinases, eNOS and GK proteins to cav-
eolae, whereas myristoylation alone appears to be
insu⁄cient. One could speculate that insertion of
the dual fatty acyl anchor into a liquid ordered lipid
domain would be energetically favorable [114], and
that this would drive partitioning of myristoylated,
palmitoylated proteins into caveolae. This hypothesis
is supported by the ¢ndings that dually acylated pro-
teins, which prefer the liquid ordered phase, are en-
riched in rafts, whereas prenylated proteins, which
have a bulky branched structure that does not par-
tition well into the liquid ordered phase, are excluded
from rafts [115] Alternatively, protein^protein inter-
actions with caveolin could drive fatty acylated pro-
teins into caveolae. Caveolin is a palmitoylated pro-
tein, but palmitoylation is not required for its
localization to caveolae [116]. Instead, palmitoylation
of caveolin appears to facilitate its interaction with
GKi subunits [101]. Interactions between caveolin
and eNOS (see below) and between caveolin and
Fyn [117] have also been reported. Caveolin appears
to provide a link between activated integrins and
Fyn, and serves as a mechanism for propagating in-
tegrin-mediated signaling [117].
The functional signi¢cance of protein localization
to rafts is best illustrated in the case of T cells. Many
of the critical signaling components involved in T-
cell receptor-mediated signaling are localized to rafts,
including the Src family kinases Fyn and Lck and the
palmitoylated, transmembrane protein LAT [118].
Activation of the T-cell receptor results in recruit-
ment of other signaling molecules to rafts, including
the zeta chain of the T-cell receptor, ZAP-70, Vav,
and PLCQ1 [119,120]. Disruption of raft structure by
agents such as ¢lipin or nystatin also disrupts early
steps of T-cell receptor activation. Likewise, muta-
tion of the palmitoylation sites within LAT prevents
LAT partitioning to rafts, and reduces LAT tyrosine
phosphorylation as well as recruitment of LAT-bind-
ing proteins such as Vav and PLC-Q1 to rafts [121].
These ¢ndings indicate that accumulation of tyrosine
phosphorylated T-cell proteins in rafts is important
for T-cell receptor-mediated signal transduction.
An additional function of raft localization appears
to be to increase local protein concentrations in or-
der to facilitate protein^protein interactions. For ex-
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ample, myristoylation and palmitoylation of Fyn
serves to localize Fyn to plasma membrane rafts
and to position its SH2 and kinase domains in close
proximity to the zeta chain of the T-cell receptor.
Phosphorylation of the zeta chain by Fyn occurs,
followed by an interaction between the Fyn SH2 do-
main and tyrosine phosphorylated residues in the
ITAM motifs of the zeta chain [122]. A chimeric
Fyn molecule which is plasma membrane bound,
but not associated with rafts, is impaired in interact-
ing with the zeta chain. Likewise, a transmembrane
version of Lck, that is plasma membrane bound, but
not fatty acylated and not raft associated, is impaired
in transducing some of the late events in T-cell re-
ceptor-mediated signaling [123]. Rafts may therefore
serve a sca¡olding function for organizing signaling
molecules into e¡ective macromolecular signaling
complexes.
3.2.3. Membrane localization by palmitoylation can
be replaced by other membrane targeting
signals
Although protein palmitoylation does play a key
role in raft localization for some proteins, there are
numerous examples where the membrane binding
function of palmitate can be replaced by another
membrane targeting signal. For example, myristoyla-
tion can substitute for palmitoylation in conferring
membrane association and transforming activity to
the oncogenic GK12 subunit [124]. The hormone re-
sponsive activity of nonacylated GKz can be restored
by coexpression with LQ subunits. Presumably the
prenyl group on the Q subunit provides the hydro-
phobicity required for membrane association and sig-
naling by an associated K subunit [96]. Fusion to
transmembrane proteins can also restore membrane
binding and signaling. For example, fusion of the
nonpalmitoylated GKi subunit to the K2A-adrenergic
receptor restores membrane binding and agonist
mediated signaling [125]. Likewise, when nonpalmi-
toylated Lck is fused to the transmembrane protein
CD16:7 the chimera can support T-cell receptor-
mediated increases in tyrosine phosphorylation and
Ca2 £ux, although transcriptional activation and
activation of MAP kinase are reduced [123].
3.2.4. Regulated depalmitoylation
It is well established that activation of GKs
through stimulation of the L-adrenergic receptor or
by mutation results in increased palmitate turnover
[126^128]. However, the functional signi¢cance of
this event has been a source of controversy. The
following model attempts to incorporate the cur-
rently available information. Activation of G protein
leads to dissociation of the Ks subunit from LQ and
depalmitoylation of Ks by a thioesterase [128,129].
Following GTP hydrolysis, Ks reassociates with LQ
and is rapidly repalmitoylated. Quantitative analyses
of the stoichiometry of Ks palmitoylation reveals that
the overall percentage of GKs that is palmitoylated
before and after receptor stimulation does not
change [130]. What is the consequence of this in-
creased palmitate turnover? Some investigators
have observed translocation of GK subunits from
the membrane to the cytosol upon receptor activa-
tion [128,131], while others maintain that GK sub-
units remain membrane bound but become concen-
trated in plasma membrane subdomains [132].
Further studies will be needed to clarify the meaning
of these di¡erent observations.
Another example of a protein whose palmitoyla-
tion levels are regulated is the endothelial form of
nitric oxide synthase (eNOS). eNOS is a myristoyl-
ated, palmitoylated protein that is localized to cav-
eolae and interacts with caveolin [133,134]. In resting
cells, caveolin-bound eNOS is inactive. Treatment
with agonists or intracellular Ca2 mobilizing agents
results in dissociation of eNOS from caveolin and
caveolae and enzyme activation [135]. Agonist treat-
ment also stimulates depalmitoylation of eNOS [136].
Since dual fatty acylation is required for localization
of eNOS to caveolae, it is tempting to link the de-
palmitoylation event with the change in eNOS local-
ization and its interaction with caveolin. However,
the situation is apparently more complex, as nonacyl-
ated eNOS can still interact with caveolin [137] and
may remain membrane bound as well [138].
4. Conclusions and perspectives
It is now clear that myristoylation and palmitoyl-
ation in£uence a wide spectrum of structural and
functional features of proteins. This review has pri-
marily focused on the role of fatty acylation in pro-
moting membrane binding and targeting. Myristoyl-
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ated proteins require a second signal for stable mem-
brane binding, and this signal is provided by a
polybasic domain or palmitate. For palmitoylated
proteins, the situation is more complex. Transmem-
brane proteins do not require palmitoylation for
membrane association and palmitoylation generally
exerts more subtle e¡ects on the structure and func-
tion of these integral membrane proteins. Many pal-
mitoylated proteins are associated with membrane
microdomains (‘rafts’) and partitioning of palmitoyl-
ated proteins into rafts has emerged as an important
aspect of signaling in T cells. Finally, it is important
to remember that protein^protein interactions also
contribute to membrane binding and targeting of
fatty acylated proteins. Moreover, fatty acid inser-
tion into cellular membranes facilitates protein^pro-
tein interactions and allows the lipid bilayer to serve
as a molecular sca¡old for organization of mem-
brane-bound signaling complexes.
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